Quest Diagnostics (DGX) Expected to Announce Quarterly Earnings on Tuesday

Quest Diagnostics (NYSE:DGX) is expected to release its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect the company to announce earnings of $2.36 per share and revenue of $2.7534 billion for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 8:30 AM ET.

Quest Diagnostics Trading Down 1.2%

DGX opened at $184.85 on Tuesday. The company has a current ratio of 1.13, a quick ratio of 1.04 and a debt-to-equity ratio of 0.71. The firm has a market cap of $20.56 billion, a price-to-earnings ratio of 21.70, a PEG ratio of 2.37 and a beta of 0.66. Quest Diagnostics has a 12 month low of $157.20 and a 12 month high of $197.55. The stock has a fifty day moving average price of $181.25 and a 200-day moving average price of $180.84.

Quest Diagnostics Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 13th were issued a $0.80 dividend. The ex-dividend date was Tuesday, January 13th. This represents a $3.20 dividend on an annualized basis and a yield of 1.7%. Quest Diagnostics’s payout ratio is currently 37.56%.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Jefferies Financial Group raised their price target on shares of Quest Diagnostics from $200.00 to $215.00 and gave the company a “buy” rating in a report on Tuesday, October 21st. Mizuho increased their target price on shares of Quest Diagnostics from $190.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, October 17th. Morgan Stanley set a $207.00 target price on shares of Quest Diagnostics and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Leerink Partners upped their price target on Quest Diagnostics from $203.00 to $210.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. Finally, Evercore ISI increased their price objective on Quest Diagnostics from $185.00 to $190.00 and gave the company an “in-line” rating in a report on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $198.27.

Insider Buying and Selling at Quest Diagnostics

In other Quest Diagnostics news, SVP Mark E. Delaney sold 7,946 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $187.35, for a total transaction of $1,488,683.10. Following the transaction, the senior vice president owned 7,530 shares in the company, valued at approximately $1,410,745.50. This represents a 51.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO J. E. Davis sold 55,093 shares of Quest Diagnostics stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $192.22, for a total transaction of $10,589,976.46. Following the sale, the chief executive officer owned 120,480 shares of the company’s stock, valued at $23,158,665.60. The trade was a 31.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 64,289 shares of company stock worth $12,318,360. 8.16% of the stock is owned by corporate insiders.

Institutional Trading of Quest Diagnostics

Several large investors have recently added to or reduced their stakes in the company. Brighton Jones LLC acquired a new position in shares of Quest Diagnostics in the fourth quarter valued at about $323,000. Cresset Asset Management LLC boosted its position in Quest Diagnostics by 4.6% in the second quarter. Cresset Asset Management LLC now owns 4,003 shares of the medical research company’s stock valued at $719,000 after buying an additional 176 shares during the last quarter. Gabelli Funds LLC acquired a new position in Quest Diagnostics in the 2nd quarter worth approximately $287,000. Bank of Nova Scotia increased its holdings in Quest Diagnostics by 7.2% in the 2nd quarter. Bank of Nova Scotia now owns 14,339 shares of the medical research company’s stock worth $2,576,000 after buying an additional 962 shares during the period. Finally, Daiwa Securities Group Inc. raised its position in Quest Diagnostics by 17.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 18,599 shares of the medical research company’s stock worth $3,341,000 after buying an additional 2,718 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.